NASDAQ · Biotechnology

CADL (CADL) Stock

$10.59 +0.09% NASDAQ: CADL Healthcare

Valuation

MetricValue
Price$10.59
Market Cap$775.93M
P/E Ratio-11.10
P/B Ratio8.44
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$11.32
52-Week Low$4.35
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-73.08%
ROA-30.40%
ROCE-92.31%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio13.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-25.0M$-35.0M$-38.0M$-33.0M$-48.0M
Net Profit$-36.0M$-19.0M$-38.0M$-55.0M$-38.0M
EPS$-1.26$-0.10$-1.31$-1.74$-0.72
Op Margin-19720.0%-27739.2%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$89.0M$79.0M$41.0M$107.0M$125.0M
Total Liabilities$25.0M$31.0M$28.0M$41.0M$73.0M
Cash$83.0M$70.0M$35.0M$103.0M$120.0M
Borrowings$1.0M$23.0M$23.0M$13.0M$2.0M

Latest News

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 8, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 1, 2026 CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’ Stocktwits · Jun 30, 2026 Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors GlobeNewswire · Jun 30, 2026 Candel Therapeutics Designates Mark Sims as CCO Exec Edge · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-22.0M$-31.0M$-34.0M$-27.0M$-38.0M
Investing Cash Flow$-4.0M$-3.0M$-1.0M$0$-1.0M
Financing Cash Flow$0$0$0$2.0M$0
Net Cash Flow$48.0M$-13.0M$-35.0M$67.0M$17.0M
Free Cash Flow$-24.0M$-33.0M$-35.0M$-27.0M$-39.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-11.17%
Quick Ratio28.05
Interest Coverage-24.00
Return 1Y41.67%
Return 3Y772.57%
Return 5Y—

Ownership

Insiders Held15.53%
Institutions Held60.02%
Institutions Float Held71.05%
Institutional HolderSharesReport Date
FMR, LLC10,987,0172026-03-31
RTW Investments LP6,422,0182026-03-31
Acorn Capital Advisors, LLC 3,497,9482026-03-31
Blackrock Inc.3,109,0422026-03-31
Saturn V Capital Management LP2,896,5882026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALDX $1.60 +3.23% -2.77 $96.51M 0.00%
CABA $2.71 -2.17% -2.23 $441.88M 0.00%
CAPR $3.93 -5.76% -50.70 $227.59M 0.00%
CTNM $14.16 +2.16% -6.62 $529.39M 0.00%
EDIT $2.62 -2.24% -1.39 $256.50M 0.00%

About CADL

CADL is led by CEO Paul-Peter Tak, employs 38 people, headquartered in US, publicly traded since 2021.

CADL stock trades at $10.59 with a market capitalization of $775.93M. The stock is valued at a price-to-earnings (P/E) ratio of -11.10, price-to-book of 8.44, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.35 and $11.32, and currently trades 6.4% below its 52-week high.

On profitability, CADL generates a return on equity (ROE) of -73.08%, return on capital employed of -92.31%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides